immuno-oncology

News

OS data set up wider Jemperli use in endometrial cancer

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th

News

NICE backs frontline use of Jemperli in endometrial cancer

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w

News

David Campbell, founder, president and CEO of Janux

Janux plans $200m offer on back of prostate cancer readout

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

OS data set up wider Jemperli use in endometrial cancer

NICE backs frontline use of Jemperli in endometrial cancer

Janux plans $200m offer on back of prostate cancer readout

New era for cell therapy as FDA OKs first for solid tumours

Gilead’s CD47 woes continue, this time in solid tumours

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks